Abdul Majeed, Chairman of Hamdard Laboratories India, shared the journey of Hamdard Foundation in an episode of TOI CXO Connect with Prasad Sanyal, Group Business Head of The Times of India. He elaborated on how Unani medicine was made accessible and patient-friendly across generations.
Unani medicine, an ancient system of healing, has undergone significant transformation under Hamdard's leadership. Majeed highlighted the efforts to modernize formulations while preserving traditional knowledge. The company focused on improving taste, packaging, and dosage forms to appeal to younger audiences without compromising efficacy.
Majeed emphasized that patient-centric innovation was key. Hamdard introduced convenient formats like syrups and tablets, replacing traditional concoctions that were less palatable. This shift helped bridge the gap between age-old remedies and modern healthcare expectations.
The chairman also discussed the role of research and development in validating Unani medicines through scientific studies. Hamdard invested in clinical trials to build credibility and trust among consumers. This approach not only retained loyal customers but also attracted new users seeking natural alternatives.
Furthermore, Majeed touched upon the importance of education and awareness. Hamdard launched campaigns to explain the principles of Unani medicine, demystifying it for the general public. The foundation's commitment to social welfare was also highlighted, with initiatives providing affordable healthcare to underserved communities.
In conclusion, Majeed expressed optimism about the future of Unani medicine, citing growing global interest in holistic health. He reiterated Hamdard's dedication to evolving with the times while staying true to its roots, ensuring that Unani medicine remains relevant for generations to come.
